



Examination Label No. EV 956473726 US Dated: April 24, 2007

Docket No.: CCI-007USDV  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Kathryn Lindsay Ball *et al.*

Application No.: 10/646,267

Confirmation No.: 9453

Filed: August 22, 2003

Art Unit: 1654

For: METHODS AND MEANS FOR INHIBITION  
OF CDK4 ACTIVITY

Examiner: D. Lukton

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (SIDS)**

Dear Sir:

In accordance with 37 CFR 1.97 and pursuant to the Examiner's comments in the Office Action dated November 24, 2006, Applicants hereby make of record the following documents originally cited in an Information Disclosure Statement filed March 26, 2004. A PTO Form SB/08 and a full copy of each of the documents required under 37 CFR 1.98(a)(2) accompany this statement.

This statement is not to be interpreted as a representation that the cited documents are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any document herein be construed *per se* as a representation that such document is prior art. Moreover, Applicants understand the Examiner will make an independent evaluation of the cited documents.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, and after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

Please charge our Deposit Account No. in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 12-0080, under Order No. CCI-007USDV.

Dated: April 24, 2007

CLK/MG/mch

Respectfully submitted,

By 

Cynthia L. Kanik, Ph.D.

Registration No.: 37,320

LAHIVE & COCKFIELD, LLP

One Post Office Square

Boston, Massachusetts 02109-2127

(617) 227-7400

(617) 742-4214 (Fax)

Attorney/Agent For Applicants



Approved for use through 03/31/2007. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			<b>Complete if Known</b> Application Number 10/646,267-Conf. #9453 Filing Date August 22, 2003 First Named Inventor Kathryn Lindsay BALL Art Unit 1654 Examiner Name D. Lukton Attorney Docket Number CCI-007USDV	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				
Sheet	1	of	2	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number Number-Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†*
		Country Code*	Number-Kind Code* (if known)				
	B1	EP-0002805-B1		07-11-1979	BASF Aktiengesellschaft		
	B2	FR-2662698-A1		12-06-1991	Centre National De La Recherche Scientifique		Abstr.
	B3	WO-93/12251-A1		06-24-1993	Baylor College of Medicine		
	B4	WO-94/02167-A1		02-03-1994	The Trustees of Princeton University		
	B5	WO-95/06415-A1		03-09-1995	Baylor College of Medicine		
	B6	WO-95/13375-A1		05-18-1995	The Johns Hopkins University		
	B7	WO-95/31995-A1		11-30-1995	Baylor College of Medicine et al.		
	B8	WO-96/14334-A1		05-17-1996	University of Dundee		
	B9	WO-97/03681-A1		02-06-1997	Worcester Foundation for Biomedical Research, Inc.		
	B10	WO-97/42222-A1		11-13-1997	Cyclacel Limited		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. †Applicant's unique citation designation number (optional). \* See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. † Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \* For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. † Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. † Applicant is to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			†*
	C1	Ball, K.L. et al., "Human and plant proliferating-cell nuclear antigen have a highly conserved binding site for the p53-inducible gene product p21WAF1," <i>Eur. J. Biochem.</i> , Vol. 237(3):854-861 (1996)			
	C2	Chen, Junjie et al., "p21Cip1/Waf1 disrupts the recruitment of human Fen1 by proliferating-cell nuclear antigen into the DNA replication complex," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 93:11597-11602 (1996)			
	C3	Chen, Junjie et al., "Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA," <i>Nature</i> , Vol. 374(6520):386-388 (1995)			
	C4	Deng, C. et al., "Mice lacking p21Cip1/WAF1 undergo normal development, but are defective in G1 checkpoint control," <i>Cell</i> , Vol. 82(4):675-684 (1995)			
	C5	Eastham, James A. et al., "In Vivo Gene Therapy with p53 of p21 Adenovirus for Prostate Cancer," <i>Cancer Research</i> , Vol. 55:5151-5155 (1995)			

Examiner Signature	Date Considered
--------------------	-----------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/646,267-Conf. #9453
				Filing Date	August 22, 2003
				First Named Inventor	Kathryn Lindsay BALL
				Art Unit	1654
				Examiner Name	D. Lukton
Sheet	2	of	2	Attorney Docket Number	CCI-007USDV

	C6	El-Deiry, W.S. et al., "WAF1, a potential mediator of p53 tumor suppression," <i>Cell</i> , Vol. 75(4):817-825 (1993)	
	C7	Flores-Rozas, Herman et al., "Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase $\delta$ holoenzyme," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 91:8655-8659 (1994)	
	C8	Gu, Yong et al., "Inhibition of CDK2 activity <i>in vivo</i> by an associated 20K regulatory subunit," <i>Nature</i> , Vol. 366:707-710 (1993)	
	C9	Harper, J. Wade et al., "The p21 Cdk-Interacting Protein Cip1 is a Potent Inhibitor of G1 Cyclin-Dependent Kinases," <i>Cell</i> , Vol. 75:805-816 (1993)	
	C10	Hiraoka, Lea R. et al., "Sequence of Human FEN-1, a Structure-Specific Endonuclease, and Chromosomal Localization of the Gene ( <i>FEN1</i> ) in Mouse and Human," <i>Genomics</i> , Vol. 25:220-225 (1995)	
	C11	Nakanishi, Makoto et al., "The C-terminal Region of P21 <sup>SDI1</sup> /WAF1/CIP1 is Involved in Proliferating Cell Nuclear Antigen Binding but Does Not Appear to Be Required for Growth Inhibition," <i>The Journal of Biological Chemistry</i> , Vol. 270(29):17060-17063 (1995)	
	C12	Su, Jin-Yuan et al., "Cloning and characterization of the <i>Xenopus</i> cyclin-dependent kinase inhibitor p27X1C1," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 92:10187-10191 (1995)	
	C13	Waga, Shou et al., "The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA," <i>Nature</i> , Vol. 369:574-578 (1994)	
	C14	Waldman, Todd et al., "p21 is Necessary for the p53-mediated G1 Arrest in Human Cancer Cells," <i>Cancer Research</i> , Vol. 55:5187-5190 (1995)	
	C15	Warbrick, Emma et al., "Homologous regions of Fen1 and p21Cip1 compete for binding to the same site on PCNA: a potential mechanism to co-ordinate DNA replication and repair," <i>Oncogene</i> , Vol. 14:2313-2321 (1997)	
	C16	Zhang, Hui et al., "p21-containing cyclin kinases exist in both active and inactive states," <i>Genes &amp; Development</i> , Vol. 8:1750-1758 (1994)	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--